KR20030025394A - Preparing Method for N-[3-{3-(1-Piperidinylmethyl)phenoxy}propyl]acetoxyacetamide - Google Patents

Preparing Method for N-[3-{3-(1-Piperidinylmethyl)phenoxy}propyl]acetoxyacetamide Download PDF

Info

Publication number
KR20030025394A
KR20030025394A KR1020010058257A KR20010058257A KR20030025394A KR 20030025394 A KR20030025394 A KR 20030025394A KR 1020010058257 A KR1020010058257 A KR 1020010058257A KR 20010058257 A KR20010058257 A KR 20010058257A KR 20030025394 A KR20030025394 A KR 20030025394A
Authority
KR
South Korea
Prior art keywords
formula
piperidinylmethyl
phenoxy
propyl
reaction
Prior art date
Application number
KR1020010058257A
Other languages
Korean (ko)
Other versions
KR100407720B1 (en
Inventor
이병석
유지상
Original Assignee
경동제약 주식회사
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 경동제약 주식회사 filed Critical 경동제약 주식회사
Priority to KR10-2001-0058257A priority Critical patent/KR100407720B1/en
Publication of KR20030025394A publication Critical patent/KR20030025394A/en
Application granted granted Critical
Publication of KR100407720B1 publication Critical patent/KR100407720B1/en

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D211/00Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/08Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms
    • C07D211/10Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with radicals containing only carbon and hydrogen atoms attached to ring carbon atoms
    • C07D211/14Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with radicals containing only carbon and hydrogen atoms attached to ring carbon atoms with hydrocarbon or substituted hydrocarbon radicals attached to the ring nitrogen atom
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445Non condensed piperidines, e.g. piperocaine
    • A61K31/4453Non condensed piperidines, e.g. piperocaine only substituted in position 1, e.g. propipocaine, diperodon
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C53/00Saturated compounds having only one carboxyl group bound to an acyclic carbon atom or hydrogen
    • C07C53/08Acetic acid
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C53/00Saturated compounds having only one carboxyl group bound to an acyclic carbon atom or hydrogen
    • C07C53/12Acetic anhydride

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Hydrogenated Pyridines (AREA)

Abstract

PURPOSE: Provided is a method of making Roxatidin, N-(3-(3-(1-piperidinylmethyl)- phenoxy)propyl)acetoxyacetamide(represented by formula 1), a H2 receptor antagonist, which is a strong anti-ulcer agent. The method is economical because one pot synthesis and mild condition are employed to produce a high yield product. CONSTITUTION: The method of synthesis of Roxatidin, N-(3-(3-(1-piperidinylmethyl)- phenoxy)propyl)acetoxyacetamide(represented by formula 1) characteristically comprises making anhydrous acetoxy acetic acid from hydroxy acetic acid and adding 3-(3-(1 piperidinylmethyl)phenoxy)propylamine in one pot reaction.

Description

N-[3-{3-(1-피페리디닐메틸)페녹시}프로필]아세톡시아세트아미드의 제조방법 {Preparing Method for N-[3-{3-(1-Piperidinylmethyl)phenoxy}propyl]acetoxyacetamide}Preparation method for N- [3- {3- (1-piperidinylmethyl) phenoxy} propyl] acetoxyacetamide {Preparing Method for N- [3- {3- (1-Piperidinylmethyl) phenoxy} propyl] acetoxyacetamide }

본 발명은 록사티딘 아세테이트로 명명되며 H2-수용체 길항제로 작용하는 하기의 화학식 1의 N-[3-{3-(1-피페리디닐메틸)페녹시}프로필]아세톡시아세트아미드의 제조방법에 관한 것이다.The present invention is made of N- [3- {3- (1-piperidinylmethyl) phenoxy} propyl] acetoxyacetamide of the following formula (1) which is named Roxatidine Acetate and acts as an H 2 -receptor antagonist It is about a method.

[화학식 1][Formula 1]

종래의 상기한 록사티딘 아세테이트의 제조방법으로서는 일본특개소 제 56-115750호, 대한민국 특허공고 제87-271호, 대한민국 특허공고 제90-5255호, 대한민국 특허공고 제91-6126호 및 대한민국 특허공고 제91-6981호가 있다.As a conventional method for producing the loxatidine acetate, Japanese Patent Application Laid-Open No. 56-115750, Korean Patent Publication No. 87-271, Korean Patent Publication No. 90-5255, Korean Patent Publication No. 91-6126 and Korean Patent Publication 91-6981.

일본특개소 제56-115750호에 따르면 하기의 반응식 1에 나타낸 바와 같이 하기의 화학식 2의 3-[3-(1-피페리디닐메틸)페녹시]프로필아민을 하기의 화학식 3의히드록시 아세트산과 반응시켜 하기의 화학식 4의 N-[3-{3-(1-피페리디닐메틸)페녹시}프로필]히드록시아세트아미드를 합성한 다음, 하기의 화학식 4의 화합물을 무수 초산과 반응시켜 목적 화합물인 하기의 화학식 1의 록사티딘 아세테이트를 제조하고 있다.According to Japanese Patent Application Laid-Open No. 56-115750, 3- [3- (1-piperidinylmethyl) phenoxy] propylamine of the following Chemical Formula 2, as shown in Scheme 1 below, is represented by hydroxy acetic acid of the following Chemical Formula 3. N- [3- {3- (1-piperidinylmethyl) phenoxy} propyl] hydroxyacetamide of the following Chemical Formula 4 was synthesized, and then the compound of Chemical Formula 4 was reacted with acetic anhydride. To prepare the loxatidine acetate of the formula (1) to the desired compound.

[반응식 1]Scheme 1

그러나, 상기한 종래의 제조 방법은 히드록시 아세트산과의 반응에 약 200℃의 고온 조건을 적용하여야 하므로 에너지 면에서 비효율적이며 작업이 어려운 단점이 있고 최종화합물까지의 합계 수율이 69.8% 정도로서 충분히 만족스럽지 못하여 비경제적이라는 문제점이 있다.However, the conventional manufacturing method described above requires high temperature conditions of about 200 ° C. for the reaction with hydroxy acetic acid, which is inefficient in energy and difficult to work with, and the total yield to the final compound is about 69.8%, which is not satisfactory enough. There is a problem of being uneconomical.

또한, 대한민국 특허공고 제87-271호는 상기한 일본특개소 제56-115750호에서의 상기한 반응식 1과 실질적으로 동일한 방법에 의해 록사티딘 아세테이트를 합성하는 방법을 기술하고 있으며, 이 종래의 방법에 있어서의 특징은 록사티딘 아세테이트 수산염을 단리함이 없이 바로 염화수소로 처리하여 록사티딘 아세테이트 염산염의 형태로 단리함으로써 수율 증대를 도모하고 있는 점이다. 그러나, 이 방법은 전술한 일본특개소 제56-115750호에서의 상기한 반응식 1과 마찬가지로 상기한화학식 4의 화합물의 합성을 위한 상기한 화학식 3의 히드록시 아세트산과 상기한 화학식 2의 화합물과의 반응에 있어 200℃의 고온 조건을 적용하여야만 하므로 에너지 효율성이 열등하여 비경제적인 문제점이 있다.In addition, Korean Patent Publication No. 87-271 describes a method for synthesizing loxatidine acetate by a method substantially the same as that of Scheme 1 described in Japanese Patent Application Laid-Open No. 56-115750. A characteristic feature of the method is that the yield is increased by treating the loxatidine acetate hydrochloride without isolating with hydrogen chloride and isolating it in the form of loxatidine acetate hydrochloride. However, this method is similar to the above-mentioned Scheme 1 in Japanese Patent Application Laid-Open No. 56-115750, in which the hydroxy acetic acid of Formula 3 and the compound of Formula 2 described above for the synthesis of the compound of Formula 4 In the reaction, high temperature conditions of 200 ° C. must be applied, resulting in inefficient economic efficiency due to inferior energy efficiency.

대한민국 특허공고 제90-5255호는 하기의 반응식 2에 나타낸 바와 같이, 하기의 화학식 2의 3-[3-(1-피페리디닐메틸)페녹시]프로필아민을 하기의 화학식 5의 아세톡시아세틸클로라이드와 반응시키는 것에 의하여 하기의 화학식 1의 록사티딘 아세테이트를 제조하고 있다.Korean Patent Publication No. 90-5255 discloses acetoxyacetyl of Formula 5 below with 3- [3- (1-piperidinylmethyl) phenoxy] propylamine of Formula 2, as shown in Scheme 2 below. By reacting with chloride to prepare the loxatidine acetate of the formula (1).

[반응식 2]Scheme 2

그러나, 상기한 종래의 방법은 고가의 원료인 아세톡시아세틸클로라이드를 사용하므로 경제성 측면에서 충분히 만족스러운 것은 못되며, 더욱이 아세톡시아세틸클로라이드는 수분에 의해 쉽게 분해되므로 저장성 및 사용성이 열등한 문제점이 있다.However, the conventional method described above does not satisfy satisfactorily in terms of economy because it uses expensive raw material acetoxyacetyl chloride. Moreover, since acetoxyacetyl chloride is easily decomposed by water, there is a problem of poor storage and usability.

록사티딘 아세테이트의 또 다른 합성법이 대한민국 특허공고 제91-6126호에 제시되어 있으며, 이에 따르면 하기의 반응식 3에 나타낸 바와 같이, 하기의 화학식 6의 3-(1-피페리디닐메틸)페놀을 하기의 화학식 7의 프로필아세톡시아세트아미드 유도체와 반응하여 목적 화합물인 록사티딘 아세테이트를 합성하고 있다.Another method for synthesizing loxatidine acetate is shown in Korean Patent Publication No. 91-6126, which indicates that 3- (1-piperidinylmethyl) phenol of Formula 6 is represented as shown in Scheme 3 below. It is reacted with a propylacetoxyacetamide derivative of the formula (7) to synthesize a loxathidine acetate as a target compound.

[반응식 3]Scheme 3

그러나, 출발물질인 상기한 화학식 7의 3-프로필아세톡시아세트아미드 유도체의 합성을 위해서는 고가이면서 불안정한 아세톡시아세틸클로라이드를 사용하여야만 하는 단점이 있다. 또한 상기한 화학식 7의 화합물은 염기에 약한 아세테이트기를 포함하는 물질로서 최종화합물의 합성단계에서 아세테이트기가 이탈되어 히드록시기로 변환될 우려가 있다. 따라서, 최종 단계의 수율도 81% 정도로서 비교적 낮아 공업적 및 경제적으로 큰 장점은 없다.However, there is a disadvantage in that expensive and unstable acetoxyacetyl chloride must be used for the synthesis of the 3-propylacetoxyacetamide derivative of Formula 7 as a starting material. In addition, the compound of Formula 7 is a substance containing an acetate group weak to the base, there is a fear that the acetate group is separated and converted to a hydroxyl group in the synthesis step of the final compound. Therefore, the yield of the final stage is also relatively low, such as 81%, there is no significant industrial and economic advantages.

마지막으로, 대한민국 특허공고 제91-6981호에 따르면, 하기의 반응식 4에 나타낸 바와 같이, 하기의 화학식 4의 N-[3-{3-(1-피페리디닐메틸)페녹시}프로필]히드록시아세트아미드를 아세틸클로라이드와 반응시켜서 록사티딘 아세테이트를 합성하는 방법을 제안하고 있다.Finally, according to Korean Patent Publication No. 91-6981, as shown in Scheme 4 below, N- [3- {3- (1-piperidinylmethyl) phenoxy} propyl] hydride of Formula 4 A method for synthesizing loxatidine acetate by reacting roxyacetamide with acetylchloride has been proposed.

[반응식 4]Scheme 4

상기한 종래의 방법은 화학식 4의 N-[3-{3-(1-피페리디닐메틸)페녹시}프로필]히드록시아세트아미드의 합성방법에 대하여 직접 기술하고 있지는 않지만, 전술한 일본 특개소 제56-115750호 또는 대한민국 특허공고 제87-271호에 기재된 것과 실질적으로 동일한 방법에 의해 합성되는 것으로 믿어지며, 이러한 관점에서 보면 상기한 화학식 4의 화합물은 전술한 바와 같이 200℃ 이상의 반응 온도조건 하에서 합성하여야 하므로 공업적으로 바람직하지 않음과 아울러, 위험하고도 비효율적인 방법이다.The conventional method described above does not directly describe a method for synthesizing N- [3- {3- (1-piperidinylmethyl) phenoxy} propyl] hydroxyacetamide of the general formula (4). It is believed to be synthesized by substantially the same method as that described in No. 56-115750 or Korean Patent Publication No. 87-271, and from this point of view, the compound of Formula 4 is a reaction temperature condition of 200 ℃ or more as described above It is not industrially desirable as it must be synthesized under the following conditions and is a dangerous and inefficient method.

본 발명자들은 전술한 종래의 기술들이 지니고 있는 문제점들을 해결하기 위하여 예의 연구를 거듭한 결과, 보다 저렴한 합성원료로부터 간단하면서도 높은 공정 효율로 항궤양제로서의 목적화합물인 록사티딘 아세테이트를 높은 수율로 제조할 수 있는 신규한 제조방법을 발견하고, 이에 기초하여 많은 노력을 기울인 결과 본 발명을 완성하기에 이르렀다.The present inventors have intensively researched to solve the problems of the above-described conventional techniques. As a result, the present inventors prepared a loxatidine acetate, which is a target compound as an anti-ulcer agent, in a high yield from a simple synthetic material with a high process efficiency. Discovering a new manufacturing method that can be done, and a lot of efforts based on this resulted in the completion of the present invention.

따라서, 본 발명의 목적은 저렴한 합성원료를 이용함으로써 코스트 다운을 도모할 수 있는 록사티딘 아세테이트의 제조방법을 제공하기 위한 것이다.Accordingly, it is an object of the present invention to provide a method for producing loxatidine acetate, which can reduce cost by using an inexpensive synthetic raw material.

본 발명의 다른 목적은 출발 원료로부터 목적화합물인 록사티딘 아세테이트를 원위치(in situ)에서 상대적으로 온화한 반응 조건하에 간단하면서도 높은 공정 효율성으로 제조할 수가 있는 제조방법을 제공하기 위한 것이다.Another object of the present invention is to provide a process for preparing a loxathidine acetate, which is a target compound, from a starting material in situ under relatively mild reaction conditions with simple and high process efficiency.

본 발명의 또 다른 목적은 목적화합물인 록사티딘 아세테이트를 높은 수율로 제조할 수가 있는 제조방법을 제공하기 위한 것이다.Still another object of the present invention is to provide a preparation method capable of producing a desired compound, loxatidine acetate, in high yield.

이하, 본 발명에 대하여 상세히 설명하기로 한다.Hereinafter, the present invention will be described in detail.

본 발명은 하기의 반응식 5에 나타낸 바와 같이, 하기의 화학식 8의 무수 아세톡시아세트산을 합성하고 이를 하기의 화학식 2의 3-[3-(1-피페리디닐메틸)페녹시]프로필아민과 유기용매 중에서 반응시키는 것에 의하여 간단하면서도 높은 수율로 목적화합물인 하기의 화학식 1의 록사티딘 아세테이트를 합성한다.As shown in Scheme 5, the present invention synthesizes anhydrous acetoxy acetic acid of Formula 8 below and organically synthesizes the compound with 3- [3- (1-piperidinylmethyl) phenoxy] propylamine of Formula 2 By reacting in a solvent, the loxatidine acetate of the following formula (1) as a target compound is synthesized in a simple and high yield.

[반응식 5]Scheme 5

상기한 반응식 5에서 상기한 화학식 8의 무수 아세톡시아세트산은 좌우대칭 구조를 갖고 있어서 부반응에 의한 불순물 생성 염려가 전혀 없으므로 상기한 화학식 1의 록사티딘 아세테이트의 합성에 매우 유용한 화합물이다.The anhydrous acetoxyacetic acid of the formula (8) in Scheme 5 is a very useful compound for the synthesis of the loxatidine acetate of the formula (1) because it has a left-right symmetric structure and there is no concern of impurities generated by side reactions.

또한, 상기한 화학식 8의 무수 아세톡시아세트산은 하기의 반응식 6에 나타낸 바와 같이, 히드록시 아세트산으로부터, 아세틸클로라이드, 티오닐클로라이드, 유기염기 등 저렴하고 구하기 용이한 원료를 사용하는 것에 의하여 용이하게 얻을 수가 있다.In addition, anhydrous acetoxy acetic acid of Formula 8 can be easily obtained from hydroxy acetic acid by using inexpensive and easily available raw materials such as acetyl chloride, thionyl chloride, organic base, and the like as shown in Scheme 6 below. There is a number.

하기의 화학식 3의 히드록시 아세트산에 용매없이 아세틸클로라이드를 가하고, 반응혼합물을 단리함이 없이 감압농축한 다음, 1/2 당량의 티오닐클로라이드를 가하여 1/2 당량의 아세톡시아세틸클로라이드을 생성시키고, 여기에 피리딘 등과 같은 적절한 유기염기를 가하면 하기의 화학식 8의 매우 순수한 무수 아세톡시아세트산을 합성할 수 있다.To hydroxy acetic acid of Formula 3, acetyl chloride was added without solvent, concentrated under reduced pressure without isolation of the reaction mixture, and then 1/2 equivalent of thionyl chloride was added to produce 1/2 equivalent of acetoxyacetyl chloride, Adding an appropriate organic base such as pyridine to it can synthesize very pure acetoxyacetic acid of the following formula (8).

[반응식 6]Scheme 6

이 반응은 하나의 반응기안에서 단리함이 없이 진행되는 반응으로 반응의 부산물들은 모두 끓는점이 낮아 단순한 감압농축만으로 제거가 가능한 장점을 가진다.This reaction is a reaction that proceeds without isolation in one reactor, the byproducts of the reaction all have a low boiling point has the advantage that can be removed by simple vacuum concentration.

또한 본 발명자들은 상기한 반응식 6과 반응식 5의 반응을 응용하여 상기한 화학식 3의 하이드록시 아세트산으로부터 별도의 용매 없이 하나의 반응기 안에서 중간화합물인 상기한 화학식 8의 무수 아세톡시아세트산을 제조하고 이를 분리하는 일 없이 상기한 화학식 2의 3-[3-(1-피페리디닐메틸)페녹시]프로필아민과 반응시켜 최종화합물인 상기한 화학식 1의 록사티딘 아세테이트를 90% 이상의 고수율로 얻을 수가 있다. 이 반응은 원위치(in situ) 반응으로서 간단하면서도 공정 효율성이 높은 장점을 가진다.In addition, the present inventors apply the reactions of Scheme 6 and Scheme 5 to prepare and separate anhydrous acetoxyacetic acid of Formula 8, which is an intermediate compound, in one reactor from the hydroxy acetic acid of Formula 3, without a separate solvent. By reacting with 3- [3- (1-piperidinylmethyl) phenoxy] propylamine of the above Chemical Formula 2, the loxatidine acetate of the above Chemical Formula 1 can be obtained in high yield of 90% or more. have. This reaction has the advantage of being simple and high in process efficiency as an in situ reaction.

(실시예)(Example)

하기한 실시예는 본 발명을 예증하기 위한 것일 뿐, 본 발명을 제한하고자 하는 것이 아님을 이해하여야만 할 것이다.It is to be understood that the following examples are merely to illustrate the invention and are not intended to limit the invention.

실시예 1 : 무수 아세톡시아세트산의 합성Example 1 Synthesis of Anhydrous Acetoxyacetic Acid

100㎖ 반응부에 5.00g의 히드록시 아세트산을 가하고 10.4㎖의 아세틸클로라이드를 가한 다음, 상온에서 16시간 동안 방치하였다. 히드록시 아세트산이 모두 용해되자 반응이 완결되었다. 이 반응 혼합물을 감압농축하여 과량 가해진 아세틸 클로라이드를 모두 제거한 다음, 50㎖의 벤젠을 가하였다. 반응부의 온도를 5℃까지 낮추고, 티오닐클로라이드 2.4㎖을 가한 다음, 다시 24시간 동안 환류 교반하였다. 다시 반응부의 온도를 0℃까지 냉각하고, 여기에 5.3㎖의 피리딘을 10㎖의 벤젠에 용해시키고 적가(滴加)하였다. 반응이 완결되었음을 확인한 다음, 생성된 피리딘 염산염을 여과하여 제거하였다. 잔사를 감압농축하여 6.65g(92.7%)의 무수아세톡시 아세트산(화학식 8)을 얻었다. 더 이상의 정제없이 다음 단계의 반응에 사용하였다.5.00 g of hydroxy acetic acid was added to the 100 ml reaction part, 10.4 ml of acetyl chloride was added thereto, and the mixture was left at room temperature for 16 hours. The reaction was complete when all of the hydroxy acetic acid had dissolved. The reaction mixture was concentrated under reduced pressure to remove any excess acetyl chloride, and then 50 ml of benzene was added. The temperature of the reaction portion was lowered to 5 ° C., 2.4 ml of thionyl chloride was added, and the mixture was further stirred at reflux for 24 hours. The temperature of the reaction portion was further cooled to 0 ° C., and 5.3 ml of pyridine was dissolved in 10 ml of benzene and added dropwise thereto. After confirming that the reaction was completed, the resulting pyridine hydrochloride was removed by filtration. The residue was concentrated under reduced pressure to give 6.65 g (92.7%) of acetoxy acetic anhydride (Formula 8). Used for the next step reaction without further purification.

1H NMR(CDCl3, 300MHz)(ppm) : 2.11(s,6H), 4.65(s,4H) 1 H NMR (CDCl 3 , 300 MHz) (ppm): 2.11 (s, 6H), 4.65 (s, 4H)

실시예 2 : N-[3-{3-(1-피페리디닐메틸)페녹시}프로필]아세톡시아세트아미드 및 그Example 2 N- [3- {3- (1-piperidinylmethyl) phenoxy} propyl] acetoxyacetamide and its

염산염의 합성Synthesis of Hydrochloride

6.31g의 3-[3-(1-피페리디닐메틸)페녹시]프로필아민을 50㎖의 클로로포름에용해시키고, 4.3㎖의 트리에칠아민을 가한 다음, 반응액의 온도를 0℃까지 냉각시켰다. 여기에 6.65g의 무수아세톡시 아세트산을 10㎖의 클로로포름에 용해시킨 용액을 천천히 적가하였다. 반응이 완결되었음을 확인한 다음, 물과 중탄산나트륨 포화 수용액을 이용하여 차례대로 유기층을 세정하고 유기층을 모았다. 모아진 유기층을 무수 황산마그네슘 상에서 건조시키고 감압농축하였다. 여기에 10㎖의 이소프로필알코올을 가하여 용해시키고, 염산으로 포화시킨 이소프로필알코올을 가하여 9.00g(92%)의 N-[3-{3-(1-피페리디닐메틸)페녹시}프로필]아세톡시아세트아미드 염산염(화학식 1의 최종 목적화합물의 염산염)을 얻었다.Dissolve 6.31 g of 3- [3- (1-piperidinylmethyl) phenoxy] propylamine in 50 mL of chloroform, add 4.3 mL of triethylamine, and then cool the reaction solution to 0 ° C. I was. To this was slowly added dropwise a solution of 6.65 g of acetoxy acetic anhydride dissolved in 10 ml of chloroform. After confirming that the reaction was completed, the organic layer was washed sequentially with water and saturated aqueous sodium bicarbonate solution, and the organic layers were collected. The combined organic layers were dried over anhydrous magnesium sulfate and concentrated under reduced pressure. 10 ml of isopropyl alcohol was added thereto to dissolve, and isopropyl alcohol saturated with hydrochloric acid was added to 9.00 g (92%) of N- [3- {3- (1-piperidinylmethyl) phenoxy} propyl] Acetoxyacetamide hydrochloride (hydrochloride of the final target compound of Formula 1) was obtained.

1H NMR(CDCl3, 300MHz)(ppm): 1.44-1.16(d,2H), 1.59-1.64(m,4H), 2.01-2.06(m,2H), 2.15(s,3H), 2.43(s,4H), 3.48(s,2H), 3.48-3.56(q,2H), 4.05-4.09(t,2H), 4.56(s,2H), 6.79-6.94(m,4H), 7.19-7.25(t,1H) 1 H NMR (CDCl 3 , 300 MHz) (ppm): 1.44-1.16 (d, 2H), 1.59-1.64 (m, 4H), 2.01-2.06 (m, 2H), 2.15 (s, 3H), 2.43 (s , 4H), 3.48 (s, 2H), 3.48-3.56 (q, 2H), 4.05-4.09 (t, 2H), 4.56 (s, 2H), 6.79-6.94 (m, 4H), 7.19-7.25 (t , 1H)

실시예 3: N-[3-{3-(1-피페리디닐메틸)페녹시}프로필]아세톡시아세트아미드 및 그Example 3: N- [3- {3- (1-piperidinylmethyl) phenoxy} propyl] acetoxyacetamide and its

염산염의 합성Synthesis of Hydrochloride

100㎖ 반응부에 5g의 히드록시 아세트산을 가하고 10.4㎖의 아세틸클로라이드를 가한 다음, 상온에서 16시간 동안 방치하였다. 히드록시 아세트산이 모두 용해되자 반응이 완결되었다. 이 반응 혼합물을 감압농축하여 과량 가해진 아세틸 클로라이드를 모두 제거한 다음, 50㎖의 벤젠을 가하였다. 반응부의 온도를 5℃까지 낮추고, 티오닐클로라이드 2.4㎖를 가한 다음, 다시 24시간 동안 환류 교반하였다.다시 반응부의 온도를 0℃까지 냉각시키고, 여기에 5.3㎖의 피리딘을 10㎖의 벤젠에 용해시켜 적가하였다. 반응이 완결되었음을 확인한 다음, 6.53g의 3-[3-(1-피페리디닐메틸)페녹시]프로필아민을 15㎖의 벤젠에 용해시킨 용액을 천천히 적가하였다. 반응이 완결되었음을 확인한 다음, 물과 중탄산나트륨 포화 수용액으로 차례대로 유기층을 세정하고 유기층을 모았다. 모아진 유기층을 무수 황산마그네슘 상에서 건조시키고 감압농축하였다. 여기에 염산으로 포화된 이소프로필알코올을 가하여 9.15g(90%)의 N-[3-{3-(1-피페리디닐메틸)페녹시}프로필]아세톡시아세트아미드 염산염(화학식 1의 최종 목적화합물의 염산염)을 얻었다.5 g of hydroxy acetic acid was added to the 100 ml reaction part, 10.4 ml of acetyl chloride was added thereto, and the mixture was left at room temperature for 16 hours. The reaction was complete when all of the hydroxy acetic acid had dissolved. The reaction mixture was concentrated under reduced pressure to remove any excess acetyl chloride, and then 50 ml of benzene was added. The temperature of the reaction portion was lowered to 5 ° C., 2.4 ml of thionyl chloride was added, followed by stirring under reflux for another 24 hours. Again, the temperature of the reaction portion was cooled to 0 ° C., and 5.3 ml of pyridine was dissolved in 10 ml of benzene. Was added dropwise. After confirming that the reaction was completed, a solution of 6.53 g of 3- [3- (1-piperidinylmethyl) phenoxy] propylamine dissolved in 15 ml of benzene was slowly added dropwise. After confirming that the reaction was completed, the organic layer was washed sequentially with water and saturated aqueous sodium bicarbonate solution, and the organic layers were collected. The combined organic layers were dried over anhydrous magnesium sulfate and concentrated under reduced pressure. 9.15 g (90%) of N- [3- {3- (1-piperidinylmethyl) phenoxy} propyl] acetoxyacetamide hydrochloride (final purpose of Formula 1) was added thereto by adding isopropyl alcohol saturated with hydrochloric acid. Hydrochloride of the compound).

1H NMR(CDCl3, 300MHz)(ppm): 1.44-1.16(d,2H), 1.59-1.64(m,4H), 2.01-2.06(m,2H), 2.15(s,3H), 2.43(s,4H), 3.48(s,2H), 3.48-3.56(q,2H), 4.05-4.09(t,2H), 4.56(s,2H), 6.79-6.94(m,4H), 7.19-7.25(t,1H) 1 H NMR (CDCl 3 , 300 MHz) (ppm): 1.44-1.16 (d, 2H), 1.59-1.64 (m, 4H), 2.01-2.06 (m, 2H), 2.15 (s, 3H), 2.43 (s , 4H), 3.48 (s, 2H), 3.48-3.56 (q, 2H), 4.05-4.09 (t, 2H), 4.56 (s, 2H), 6.79-6.94 (m, 4H), 7.19-7.25 (t , 1H)

전술한 바와 같이, 본 발명에 따른 록사티딘 아세테이트의 제조방법은 저렴한 합성원료를 이용함으로써 코스트 다운을 도모할 수 있으며, 출발 원료로부터 목적화합물인 록사티딘 아세테이트를 원위치(in situ)에서 온화한 반응 조건하에 간단하면서도 높은 수율로 제조할 수가 있는 효율성 높은 경제적인 제조방법이다.As described above, the method for preparing the loxatidine acetate according to the present invention can reduce the cost by using an inexpensive synthetic raw material, and a gentle reaction in situ of the loxatidine acetate as a target compound from the starting raw material. It is an efficient and economical manufacturing method that can be manufactured in a simple and high yield under the conditions.

Claims (3)

하기의 화학식 2의 3-[3-(1-피페리디닐메틸)페녹시]프로필아민과 하기의 화학식 8의 무수 아세톡시아세트산을 반응시키는 것으로 구성되는 하기의 화학식 1의 록사티딘 아세테이트의 제조방법.Preparation of Roxatidine Acetate of Formula 1, consisting of reacting 3- [3- (1-piperidinylmethyl) phenoxy] propylamine of Formula 2 with anhydrous acetoxyacetic acid of Formula 8 Way. (화학식 2)(Formula 2) (화학식 8)(Formula 8) (화학식 1)(Formula 1) 하기의 화학식 3의 하이드록시 아세트산으로부터 하기의 화학식 8의 무수아세톡시 아세트산을 합성하고, 원위치에서(in situ) 하기의 화학식 2의 3-[3-(1-피페리디닐메틸)페녹시]프로필아민을 가하는 단일 스텝으로 구성되는 하기의 화학식 1의 록사티딘 아세테이트의 제조방법.From the hydroxy acetic acid of formula (3) below acetoxy acetic anhydride of formula (8) was synthesized and in situ 3- [3- (1-piperidinylmethyl) phenoxy] propyl of formula (2) A process for preparing the loxatidine acetate of formula (I), consisting of a single step of adding an amine. (화학식 3)(Formula 3) (화학식 8)(Formula 8) (화학식 2)(Formula 2) (화학식 1)(Formula 1) 제1항 또는 제2항에 있어서, 하기한 화학식 8의 무수아세톡시 아세트산이 하기의 화학식 3의 화합물에 아세틸클로라이드, 할로겐화제 및, 유기염기를 순차적으로 가하여 반응시키는 것에 의해 제조되는 록사티딘 아세테이트의 제조방법.The loxathidine acetate according to claim 1 or 2, wherein acetoxy acetic anhydride of formula (8) is prepared by sequentially adding acetyl chloride, a halogenating agent, and an organic base to the compound of formula (3). Manufacturing method. (화학식 8)(Formula 8) (화학식 3)(Formula 3)
KR10-2001-0058257A 2001-09-20 2001-09-20 Preparing Method for N-[3-{3-(1-Piperidinylmethyl)phenoxy}propyl]acetoxyacetamide KR100407720B1 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
KR10-2001-0058257A KR100407720B1 (en) 2001-09-20 2001-09-20 Preparing Method for N-[3-{3-(1-Piperidinylmethyl)phenoxy}propyl]acetoxyacetamide

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
KR10-2001-0058257A KR100407720B1 (en) 2001-09-20 2001-09-20 Preparing Method for N-[3-{3-(1-Piperidinylmethyl)phenoxy}propyl]acetoxyacetamide

Publications (2)

Publication Number Publication Date
KR20030025394A true KR20030025394A (en) 2003-03-29
KR100407720B1 KR100407720B1 (en) 2003-12-01

Family

ID=27724893

Family Applications (1)

Application Number Title Priority Date Filing Date
KR10-2001-0058257A KR100407720B1 (en) 2001-09-20 2001-09-20 Preparing Method for N-[3-{3-(1-Piperidinylmethyl)phenoxy}propyl]acetoxyacetamide

Country Status (1)

Country Link
KR (1) KR100407720B1 (en)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20030079456A (en) * 2002-04-04 2003-10-10 바이오네스트 주식회사 A process for the preparation of roxatidine acetate or pharmaceutically acceptable salts thereof
CN114276314A (en) * 2021-12-31 2022-04-05 广安凯特制药有限公司 High-purity roxatidine acetate hydrochloride and preparation method thereof

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR870001162B1 (en) * 1985-06-07 1987-06-15 더 다우 케미칼 캄파니 Preparation process of cyclobutene-substituted aromatic hydrocarbons
EP0404949A4 (en) * 1988-07-05 1991-07-17 Zeria Pharmaceutical Co., Ltd. Substituted acetamide derivatives, process for their preparation and antiulcer drug containing same
JPH0692948A (en) * 1992-03-04 1994-04-05 Snow Brand Milk Prod Co Ltd Novel acetamide derivative and its use

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20030079456A (en) * 2002-04-04 2003-10-10 바이오네스트 주식회사 A process for the preparation of roxatidine acetate or pharmaceutically acceptable salts thereof
CN114276314A (en) * 2021-12-31 2022-04-05 广安凯特制药有限公司 High-purity roxatidine acetate hydrochloride and preparation method thereof

Also Published As

Publication number Publication date
KR100407720B1 (en) 2003-12-01

Similar Documents

Publication Publication Date Title
JP5457555B2 (en) Method for producing tricyclic derivative
KR20010053294A (en) Method for producing ortho-alkylated benzoic acid derivatives
KR100407720B1 (en) Preparing Method for N-[3-{3-(1-Piperidinylmethyl)phenoxy}propyl]acetoxyacetamide
KR100743617B1 (en) Process for the preparation of chiral 3-hydroxy pyrrolidine compound and derivatives thereof having high optical purity
JP3831954B2 (en) Process for producing 4-hydroxy-2-pyrrolidone
JP2001521498A (en) Method for producing O- (3-amino-2-hydroxy-propyl) -hydroxymic acid halide
JPH0737440B2 (en) Method for producing sulfonium compound
CN108137485A (en) The preparation method of benzoic acid amide compound
US5380849A (en) Process for optically pure decahydroisoqiunolines
KR100296737B1 (en) The Process of Aceclofenac
CN111662233B (en) Method for synthesizing 4-chloro-1H-imidazole-2-carboxylic acid ethyl ester by one-step method
KR100288404B1 (en) 2-Benzothiazolyl 4-amino-5-chloro-2-methoxythiobenzoate And Process For Preparing Cisapride Employing The Same
KR100432587B1 (en) Method of preparing levosulpiride and intermediates used therein
JP2003137835A (en) Method for producing (r)-3-hydroxy-3-(2-phenyl)hexanoic acid
KR100483317B1 (en) METHOD FOR THE PREPARATION OF α-PHENYL-α-PROPOXYBENZENEACETIC ACID 1-METHYL-4-PIPERIDINYL ESTER HYDROCHLORIDE
KR100468314B1 (en) Intermediate for preparing levosulpiride and preparation method thereof
JP3669726B2 (en) Process for producing optically active 3- (p-alkoxyphenyl) glycidic acid ester derivative
JPS62167754A (en) Production of cyanomethylthioacetic acids
JPH09110775A (en) Production of 1-naphthaldehyde
JP3013760B2 (en) Method for producing 4-hydroxy-2-pyrrolidone
KR100230900B1 (en) Pyrrolidine derivatives and process for preparing the same
KR100896087B1 (en) Synthetic method of optically pure 2-methylpyrrolidine and the salt thereof
JP2004026790A (en) Pyrrolidine derivative and method for producing the same
KR101142052B1 (en) Method of preparing zanamivir
JPH10338679A (en) Production of thiazolidine derivative

Legal Events

Date Code Title Description
A201 Request for examination
E701 Decision to grant or registration of patent right
GRNT Written decision to grant
FPAY Annual fee payment

Payment date: 20101224

Year of fee payment: 9

FPAY Annual fee payment

Payment date: 20111228

Year of fee payment: 12

FPAY Annual fee payment

Payment date: 20150106

Year of fee payment: 15